Now there’s one more alternative medication for GERD, soon to be released from Takeda as Prevacid nears patent expiration. As the article states, choices for treatment of GERD certainly are not limited and this is really nothing new as many drugs have been re-created with the same type of time released actions. BD
Deerfield-based Takeda Pharmaceuticals North America Inc. said Friday evening its heartburn drug Kapidex was approved by the Food and Drug Administration, entering the crowded field of prescription proton pump inhibitors.
The FDA approved Kapidex "delayed release capsules" for the treatment of gastroesophageal reflux disease, commonly known as GERD. Kapidex is in the same proton pump inhibitor class of drugs as Takeda's Prevacid, which loses patent protection later this year and faces competition from cheaper generics.
FDA approves Takeda's latest heartburn drug Kapidex -- chicagotribune.com
This tactic has been employed by the pharmaceutical industry for years. It has become standard operating procedure as an attempt to continue to generate revenue from pharmaceuticals as they near the end of their patent life.
ReplyDeleteYes I agree, it has gone on for years and one way to generate additional income with competing with generics drugs.
ReplyDelete